Skip to main content
Image coming soon

Board-Level AI in Pharmaceutical R&D Operations for Compliance Officers

$199.00
Adding to cart… The item has been added

A tailored course, built for your situation

Board-Level AI in Pharmaceutical R&D Operations for Compliance Officers

Master the governance, risk, and compliance frameworks for AI-driven drug development at the executive level

$199 one-time
24-hour access provisioning 30-day money-back guarantee Hand-built implementation playbook
12 modules. 12 chapters per module. 144 chapters total.
12 modules, each with 12 chapters (144 chapters total), text-based, plus downloadable templates and a hand-built implementation playbook delivered alongside course access.
Compliance leaders are being asked to validate AI systems they don’t fully understand, in high-stakes R&D contexts with evolving regulatory expectations.

The situation this course is for

AI adoption in pharmaceutical R&D is accelerating, but compliance functions often lag in technical fluency and strategic influence. Without a structured framework, professionals risk being sidelined in critical decisions or issuing oversight that lacks technical grounding. The pressure to ensure auditability, reproducibility, and ethical alignment grows with every AI-assisted trial and predictive development model.

Who this is for

Strategic compliance, risk, or GRC professionals in mid-to-large pharmaceutical organizations or CROs who engage with R&D leadership and must govern AI-enabled innovation with confidence.

Who this is not for

Entry-level compliance staff, AI engineers without governance responsibilities, or professionals focused solely on non-R&D business units like marketing or HR.

What you walk away with

  • Apply board-ready AI governance frameworks specific to pharmaceutical R&D
  • Evaluate AI model risk in clinical trial design and drug discovery pipelines
  • Align AI deployment with FDA, EMA, and ICH regulatory expectations
  • Develop audit trails and compliance documentation for AI-augmented R&D processes
  • Communicate AI risk and opportunity effectively to executive and board audiences

The 12 modules (with all 144 chapters)

Module 1. AI Governance in Pharmaceutical R&D: Strategic Foundations
Establish the executive-level principles of AI governance tailored to drug development environments.
12 chapters in this module
  1. Defining AI governance maturity in pharma
  2. The evolving role of compliance in R&D innovation
  3. Board expectations for AI oversight
  4. Regulatory landscape overview: FDA, EMA, ICH
  5. Risk-based prioritization of AI use cases
  6. Stakeholder mapping: R&D, compliance, legal, IT
  7. AI ethics frameworks in life sciences
  8. Case study: AI governance failure in Phase III trial design
  9. Building a cross-functional AI governance team
  10. Developing a compliance playbook for AI projects
  11. Measuring governance effectiveness
  12. Integrating AI oversight into enterprise risk management
Module 2. AI Model Risk Management in Regulated R&D
Implement model risk controls specific to pharmaceutical AI applications.
12 chapters in this module
  1. Model risk principles in FDA-regulated contexts
  2. Lifecycle management for AI models in drug discovery
  3. Validation strategies for predictive toxicology models
  4. Bias detection in patient recruitment algorithms
  5. Transparency requirements for black-box models
  6. Version control and reproducibility in AI pipelines
  7. Audit readiness for model documentation
  8. Stress testing AI models under regulatory scrutiny
  9. Third-party model risk assessment
  10. Model drift monitoring in long-term trials
  11. Incident response for model failures
  12. Regulatory inspection preparation for AI systems
Module 3. AI in Drug Discovery: Compliance by Design
Embed compliance into AI-driven target identification and compound screening.
12 chapters in this module
  1. Overview of AI in target identification
  2. Data provenance requirements for training sets
  3. IP considerations in AI-generated compounds
  4. Regulatory classification of AI-discovered molecules
  5. Compliance checkpoints in virtual screening
  6. Audit trails for generative chemistry models
  7. Validation of docking prediction accuracy
  8. Ethical sourcing of biological data
  9. Cross-border data transfer in discovery consortia
  10. Documentation standards for AI-assisted lead optimization
  11. Interfacing with preclinical safety teams
  12. Preparing discovery dossiers for regulatory review
Module 4. AI-Augmented Clinical Trials: Risk and Oversight
Govern AI applications in trial design, recruitment, and endpoint analysis.
12 chapters in this module
  1. AI in adaptive trial design: regulatory boundaries
  2. Algorithmic patient selection and bias mitigation
  3. Real-world data integration compliance
  4. Informed consent in AI-informed trials
  5. Monitoring AI-driven endpoint prediction
  6. Data integrity in decentralized trials
  7. Validation of wearable-derived endpoints
  8. Compliance with 21 CFR Part 11 for AI systems
  9. Audit trails for AI-assisted monitoring
  10. Handling protocol deviations flagged by AI
  11. Regulatory reporting of AI-influenced decisions
  12. Post-trial review of AI performance
Module 5. Regulatory Submissions with AI-Generated Evidence
Prepare and validate submissions that include AI-derived data and conclusions.
12 chapters in this module
  1. FDA guidance on AI in regulatory submissions
  2. Demonstrating robustness of AI-generated analyses
  3. Documentation requirements for machine learning models
  4. Validation of AI-assisted biomarker discovery
  5. Reproducibility standards for submission packages
  6. Handling model updates during review cycles
  7. Cross-agency alignment on AI evidence
  8. Responding to regulator queries on AI methods
  9. Version control in submission datasets
  10. Audit preparation for AI-backed claims
  11. Case study: AI-supported BLA submission
  12. Future trends in digital submission standards
Module 6. Data Governance for AI in Pharmaceutical R&D
Ensure data quality, lineage, and compliance across AI training and inference.
12 chapters in this module
  1. Data governance maturity in pharma AI
  2. Defining data ownership in cross-functional teams
  3. Data quality metrics for AI readiness
  4. Lineage tracking in multi-source datasets
  5. Anonymization standards for patient data
  6. Compliance with GDPR and HIPAA in AI contexts
  7. Data access controls in collaborative research
  8. Audit logging for data transformations
  9. Metadata standards for AI training sets
  10. Data versioning and reproducibility
  11. Handling data drift in long-running models
  12. Data retention policies for regulatory audits
Module 7. AI Vendor and Third-Party Risk Management
Assess and govern external AI providers in R&D partnerships.
12 chapters in this module
  1. Due diligence for AI vendors in pharma
  2. Contractual requirements for AI deliverables
  3. Audit rights for third-party models
  4. IP ownership in co-developed AI systems
  5. Service provider compliance with GxP
  6. Assessing vendor model validation practices
  7. Onboarding AI platforms into secure environments
  8. Monitoring ongoing vendor performance
  9. Exit strategies for AI vendor relationships
  10. Regulatory implications of offshore AI development
  11. Case study: vendor-related AI compliance failure
  12. Building a third-party AI risk register
Module 8. AI Ethics and Patient Safety in R&D
Integrate ethical review and safety oversight into AI-driven research.
12 chapters in this module
  1. Ethical principles for AI in human research
  2. Patient autonomy in AI-informed consent
  3. Bias assessment in diverse population models
  4. Equity in AI-driven trial access
  5. Safety monitoring for AI-recommended dosing
  6. Transparency with patients about AI use
  7. Ethics committee engagement strategies
  8. Handling unintended algorithmic consequences
  9. Reporting AI-related adverse events
  10. Global harmonization of AI ethics standards
  11. Public trust and AI in drug development
  12. Case study: ethical lapse in AI trial recruitment
Module 9. Board Communication and Executive Reporting
Translate technical AI risk into strategic board-level insights.
12 chapters in this module
  1. Defining board-level AI risk metrics
  2. Reporting frequency and format standards
  3. Visualizing AI risk exposure for executives
  4. Balancing innovation and compliance narratives
  5. Preparing for board AI inquiries
  6. Scenario planning for AI incidents
  7. Linking AI governance to enterprise strategy
  8. Benchmarking against peer organizations
  9. Communicating audit findings to leadership
  10. Managing board expectations on AI ROI
  11. Crisis communication for AI failures
  12. Building executive confidence in AI oversight
Module 10. AI Audit Readiness and Inspection Preparedness
Ensure AI systems in R&D are inspection-ready and defensible.
12 chapters in this module
  1. Preparing for FDA AI-focused inspections
  2. Documenting model development lifecycle
  3. Audit trail completeness for AI decisions
  4. Training records for AI system operators
  5. Version control evidence for models and data
  6. Handling regulator requests for code access
  7. Mock audits for AI governance processes
  8. Corrective action plans for findings
  9. Regulatory correspondence management
  10. Post-inspection follow-up procedures
  11. Continuous improvement of audit readiness
  12. Case study: successful AI audit in biotech
Module 11. AI Policy Development and Internal Standards
Create and enforce organization-wide AI compliance policies.
12 chapters in this module
  1. Developing a corporate AI governance policy
  2. Setting internal AI risk thresholds
  3. Approval workflows for AI project initiation
  4. Role-based access in AI systems
  5. Training requirements for R&D staff
  6. Incident reporting procedures for AI issues
  7. Policy enforcement and accountability
  8. Review cycles for AI standards
  9. Aligning policy with international guidelines
  10. Communicating policy changes across functions
  11. Measuring policy adoption and effectiveness
  12. Updating policy in response to regulatory shifts
Module 12. Future-Proofing AI Governance in Pharma R&D
Anticipate emerging trends and build adaptive compliance frameworks.
12 chapters in this module
  1. Emerging AI technologies in drug development
  2. Regulatory anticipation strategies
  3. Building organizational agility in governance
  4. Scenario planning for disruptive AI
  5. Investing in compliance automation
  6. Talent development for AI-savvy teams
  7. Collaborating with regulatory sandboxes
  8. Engaging in industry AI standards bodies
  9. Monitoring global AI policy developments
  10. Adaptive framework design principles
  11. Long-term vision for AI compliance leadership
  12. Sustaining innovation while ensuring trust

How this maps to your situation

  • Compliance officer reviewing AI trial design protocol
  • R&D leader justifying AI investment to board
  • Quality assurance manager preparing for FDA audit
  • GRC professional building AI risk framework

Before vs. after

Before
Uncertain about how to govern AI systems in R&D, relying on general compliance principles without technical depth or regulatory specificity.
After
Equipped with a structured, implementation-grade framework to lead AI governance in pharmaceutical R&D with confidence, clarity, and board-level authority.

What's included with your purchase

  • 12 modules with 12 chapters each (144 chapters)
  • Downloadable templates and worked examples for every module
  • Hand-built implementation playbook delivered alongside course access
  • 30-day money-back guarantee

Delivery and format

  • Course and learning environment access provisioned within 24 hours of purchase
  • Hand-built implementation playbook delivered alongside course access

Format: Text-based modules and chapters in the Art of Service learning environment, plus downloadable templates and worked examples for every chapter, plus the hand-built implementation playbook delivered alongside course access.

Time investment: Approximately 60, 70 hours of self-paced learning, designed for busy professionals balancing full-time roles.

If nothing changes
Without structured AI governance knowledge, compliance professionals risk being bypassed in critical R&D decisions, issuing oversight that lacks technical credibility, or failing to meet evolving regulatory expectations for algorithmic accountability.

How this compares to the alternatives

Unlike generic AI ethics courses or technical machine learning programs, this course is specifically tailored to the intersection of pharmaceutical R&D, regulatory compliance, and board-level governance, providing actionable frameworks you won’t find in academic or vendor-led training.

Frequently asked

Who is this course designed for?
Compliance, risk, and governance professionals in pharmaceutical or biotech organizations who engage with R&D leadership and must oversee AI systems in drug development.
How is the course structured?
12 modules, each containing 12 chapters (144 chapters total).
Is prior AI experience required?
No. The course builds from foundational concepts to advanced implementation, making it accessible to compliance leaders new to AI while still valuable for those with technical exposure.
$199 one-time. Approximately 60, 70 hours of self-paced learning, designed for busy professionals balancing full-time roles..

Within 24 hours your account in the learning environment is provisioned and the tailored implementation playbook is delivered alongside it.

30-day money-back guarantee· 144 chapters· Hand-built playbook included· Account access within 24 hours
!